Skip to main content
main-content

01.12.2015 | Research article | Ausgabe 1/2015 Open Access

BMC Musculoskeletal Disorders 1/2015

How much do rheumatologists and orthopaedists doctors’ modalities impact the cost of arthritis in Cyprus?

Zeitschrift:
BMC Musculoskeletal Disorders > Ausgabe 1/2015
Autoren:
Despena Andrioti, Kypros Kyprianou, George Charalambous
Wichtige Hinweise

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

DA contributed to the study’s conception and design, interpretation of data, and drafted the manuscript. KK was involved in acquisition of data, performed statistical analyses and helped to draft the manuscript. GC was involved in the design of the study, data interpretation, and critically revised the manuscript. All authors read and approved the final manuscript.

Abstract

Background

Osteoarthritis is one of the primary causes of long-term functional disability. With an estimated 13.5 % prevalence in the general population contributes to a significant financial burden both for patients and healthcare systems. The purpose of this research is to highlight the direct annual cost of the disease to the private healthcare sector of Nicosia.

Methods

A questionnaire based on Greek and international research was completed between 10/1/2012 and 11/30/2012, with a sample of 20 doctors specialists in orthopaedics and rheumatology (50 % of practising physicians in the private sector). An assessment of the annual cost of medical procedures and tests, pharmacologic therapies (modalities) and supplies per patient followed, based on current costs. Direct costs were assessed through the micro-costing “bottom-up” approach. We isolated and separately priced the original diagnosis, followed by each stage of the disease.

Results

The cost for the six predominant medical tests to establish a diagnosis and exclude mainly RA such as ESR, CPR, and X-ray as well as a physician’s office visit was 150€ per patient. The average direct cost per patient during stages 1, 2 and 3 of the disease was 280.54€, 1,834.64€ and 5,641.72€ annually, respectively, with an annual average of 2,573€ per patient.

Conclusions

Even though during the period of the study, the country had not yet established clinical guidelines, the participating physicians followed international practices. Significant rise in the cost in each stage of the disease was found, with additional increases in the following years as a result of the expected increased prevalence of the disease. It is noted here that uninsured patients, as well as those who qualified for free medical care, they seek these services in the private sector, and had to pay out of pocket money for examination and treatment. These patients, thus, contended with a serious financial burden. Therefore, it is important to inform them very extensively regarding evidence-based management of the disease to aid them in coping with this chronic illness.
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2015

BMC Musculoskeletal Disorders 1/2015 Zur Ausgabe

Neu im Fachgebiet Orthopädie und Unfallchirurgie

21.11.2019 | ACR 2019 | Kongressbericht | Onlineartikel

Anifrolumab bei SLE nun doch mit signifikanten Ergebnissen

21.11.2019 | ACR 2019 | Kongressbericht | Onlineartikel

Handarthrose: Tops und Flops vom ACR-Kongress

21.11.2019 | ACR 2019 | Kongressbericht | Onlineartikel

JAK - selektive Inhibitoren bei RA mit Vorteilen?

21.11.2019 | ACR 2019 | Kongressbericht | Onlineartikel

Erste Daten zur Differentialtherapie der PsA

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Orthopädie und Unfallchirurgie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise